Genome Pharmaceuticals, Altana AG deal

Genome Pharmaceuticals and Altana subsidiary Byk Gulden (Konstanz, Germany) will collaborate on new genomic targets to control infections caused by Helicobacter pylori and Chlamydia pneumoniae. Genome Pharmaceuticals will provide its automated genomics and proteomics technologies and bioinformatics, while Byk Gulden will use the targets as starting points to develop drugs and diagnostics. The deal is worth up to DM50 million (US$30 million) to Genome Pharmaceuticals, including R&D support and milestones. ...